{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:00:01Z","timestamp":1790049601310,"version":"4.0.1"},"reference-count":132,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RO-5435\/3-1"],"award-info":[{"award-number":["RO-5435\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FA-466\/8-1"],"award-info":[{"award-number":["FA-466\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FA-466-4-2"],"award-info":[{"award-number":["FA-466-4-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR 4371\/1\\u20132"],"award-info":[{"award-number":["KR 4371\/1\\u20132"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271 \\u2013 TRR 205"],"award-info":[{"award-number":["314061271 \\u2013 TRR 205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271"],"award-info":[{"award-number":["314061271"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR 205"],"award-info":[{"award-number":["TRR 205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113526"],"award-info":[{"award-number":["70113526"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.beem.2020.101434","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T02:42:24Z","timestamp":1592448144000},"page":"101434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Next-generation therapies for adrenocortical carcinoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Barbara","family":"Altieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina L.","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2020.101434_bib1","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/EJE-13-0142","article-title":"Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data","volume":"169","author":"Kerkhofs","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician's update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2020.101434_bib5","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2020.101434_bib7","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Libe","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1530\/EJE-18-0450","article-title":"Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis","volume":"179","author":"Vanbrabant","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib9","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2020.101434_bib10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assie","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2020.101434_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Canc Cell"},{"key":"10.1016\/j.beem.2020.101434_bib13","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2018-01348","article-title":"Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication","volume":"103","author":"Lippert","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib14","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1210\/jc.2010-0803","article-title":"Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers","volume":"95","author":"Fassnacht","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1245\/s10434-015-4810-y","article-title":"Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence","volume":"23","author":"Amini","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib16","first-page":"963","article-title":"An eleven-year experience with adrenocortical carcinoma","volume":"112","author":"Pommier","year":"1992","journal-title":"Surgery"},{"key":"10.1016\/j.beem.2020.101434_bib17","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib18","article-title":"Mitotane concentrations influence the risk of recurrence in adrenocortical carcinoma patients on adjuvant treatment","volume":"8","author":"Puglisi","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.beem.2020.101434_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030740","article-title":"Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma","volume":"vol. 12","author":"Puglisi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2020.101434_bib20","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1210\/jc.2010-2676","article-title":"Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study","volume":"96","author":"Hermsen","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib21","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1210\/en.2015-1367","article-title":"Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells","volume":"156","author":"Sbiera","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2020.101434_bib22","doi-asserted-by":"crossref","first-page":"109924","DOI":"10.18632\/oncotarget.18968","article-title":"Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches","volume":"8","author":"Hescot","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.beem.2020.101434_bib23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1210\/clinem\/dgz001","article-title":"The efficacy of mitotane in human primary adrenocortical carcinoma cultures","volume":"105","author":"van Koetsveld","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010247","article-title":"Sterol O-acyl transferase 1 as a prognostic marker of adrenocortical carcinoma","volume":"12","author":"Lacombe","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2020.101434_bib25","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa293","article-title":"Expression of SOAT1 in adrenocortical carcinoma and response to mitotane monotherapy: an ENSAT multicenter study","author":"Weigand","year":"2020","journal-title":"Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib26","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-11-2692","article-title":"Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer","volume":"18","author":"Volante","year":"2012","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/FPC.0b013e3283606cb2","article-title":"Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane","volume":"23","author":"D'Avolio","year":"2013","journal-title":"Pharmacogenetics Genom"},{"key":"10.1016\/j.beem.2020.101434_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105855","article-title":"CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma","volume":"9","author":"Ronchi","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.beem.2020.101434_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020359","article-title":"Effects of germline CYP2W1\u22176 and CYP2B6\u22176 single nucleotide polymorphisms on mitotane treatment in adrenocortical carcinoma: a multicenter ENSAT study","volume":"12","author":"Altieri","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2020.101434_bib30","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2020.101434_bib31","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"Br J Canc"},{"key":"10.1016\/j.beem.2020.101434_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/ERC-17-0095","article-title":"Topoisomerase 2alpha and thymidylate synthase expression in adrenocortical cancer","volume":"24","author":"Roca","year":"2017","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.beem.2020.101434_bib33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1677\/ERC-08-0224","article-title":"Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy","volume":"16","author":"Ronchi","year":"2009","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.beem.2020.101434_bib34","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1677\/ERC-09-0341","article-title":"Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma","volume":"17","author":"Malandrino","year":"2010","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.beem.2020.101434_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/EJE-17-0788","article-title":"ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas","volume":"178","author":"Laufs","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.beem.2020.101434_bib37","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience","volume":"12","author":"Lagana","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2020.101434_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/a-0715-1946","article-title":"Advanced adrenocortical carcinoma - what to do when first-line therapy fails?","volume":"127","author":"Megerle","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2020.101434_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12672-016-0260-7","article-title":"Salvage treatment of adrenocortical carcinoma with trofosfamide","volume":"7","author":"Kroiss","year":"2016","journal-title":"Horm Canc"},{"key":"10.1016\/j.beem.2020.101434_bib41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/a-0747-5571","article-title":"Treatment of refractory adrenocortical carcinoma with thalidomide: analysis of 27 patients from the European Network for the study of adrenal tumours registry","volume":"127","author":"Kroiss","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2020.101434_bib42","first-page":"43","article-title":"The role of insulin-like growth factor system in the adrenocortical tumors","volume":"44","author":"Altieri","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib43","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/ijc.29950","article-title":"Adrenocortical tumors and insulin resistance: what is the first step?","volume":"138","author":"Altieri","year":"2016","journal-title":"Int J Canc"},{"key":"10.1016\/j.beem.2020.101434_bib44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12020-019-01869-1","article-title":"IGF and mTOR pathway expression and in\u00a0vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer","volume":"64","author":"De Martino","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2020.101434_bib45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2008-1456","article-title":"Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma","volume":"94","author":"Barlaskar","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib46","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1210\/jc.2008-0065","article-title":"Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors","volume":"93","author":"Almeida","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib47","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.beem.2020.101434_bib48","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-10-2979","article-title":"Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer","volume":"17","author":"Naing","year":"2011","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.beem.2020.101434_bib50","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014","journal-title":"Horm Canc"},{"key":"10.1016\/j.beem.2020.101434_bib51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1158\/1078-0432.CCR-14-0265","article-title":"Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors","volume":"21","author":"Jones","year":"2015","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib52","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib53","doi-asserted-by":"crossref","first-page":"49636","DOI":"10.18632\/oncotarget.10421","article-title":"Metformin as a new anti-cancer drug in adrenocortical carcinoma","volume":"7","author":"Poli","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.beem.2020.101434_bib54","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1530\/EC-19-0224","article-title":"The role of mTOR pathway as target for treatment in adrenocortical cancer","volume":"8","author":"De Martino","year":"2019","journal-title":"Endocr Conn"},{"key":"10.1016\/j.beem.2020.101434_bib55","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10637-013-0013-1","article-title":"Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer","volume":"31","author":"Ganesan","year":"2013","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.beem.2020.101434_bib56","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","volume":"4","author":"Wagle","year":"2014","journal-title":"Canc Discov"},{"key":"10.1016\/j.beem.2020.101434_bib57","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/ERC-11-0337","article-title":"Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models","volume":"19","author":"Mariniello","year":"2012","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.beem.2020.101434_bib58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fendo.2011.00027","article-title":"Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells","volume":"2","author":"Kroiss","year":"2011","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib59","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib60","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib61","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1530\/EJE-10-0956","article-title":"Mitotane has a strong and a durable inducing effect on CYP3A4 activity","volume":"164","author":"van Erp","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib63","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/JOE-12-0297","article-title":"Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor","volume":"216","author":"Takeshita","year":"2013","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib64","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O'Sullivan","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib65","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1200\/jco.2014.32.15_suppl.4588","article-title":"Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03","volume":"32","author":"Garc\u00eda-Donas","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib66","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-09-0804","article-title":"Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma","volume":"162","author":"Wortmann","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib67","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1158\/0008-5472.CAN-14-3707","article-title":"Hepatocyte growth factor\/cMET pathway activation enhances cancer hallmarks in adrenocortical carcinoma","volume":"75","author":"Phan","year":"2015","journal-title":"Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib68","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib69","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/modpathol.2010.153","article-title":"Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome","volume":"23","author":"Adam","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.beem.2020.101434_bib70","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bcp.2015.10.012","article-title":"Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors","volume":"98","author":"Gagliano","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.beem.2020.101434_bib71","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib72","doi-asserted-by":"crossref","first-page":"15527","DOI":"10.1200\/jco.2007.25.18_suppl.15527","article-title":"A\u00a0phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC)","volume":"25","author":"Samnotra VV-S","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib73","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thorsurg.2020.01.008","article-title":"Epidermal growth factor receptor mutations","volume":"30","author":"McLoughlin","year":"2020","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.beem.2020.101434_bib74","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1210\/jc.2013-2165","article-title":"Molecular screening for a personalized treatment approach in advanced adrenocortical cancer","volume":"98","author":"De Martino","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib75","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-08-1067","article-title":"Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling","volume":"15","author":"Giordano","year":"2009","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib76","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A\u00a0Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br J Canc"},{"key":"10.1016\/j.beem.2020.101434_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-15-0527","article-title":"ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in\u00a0vivo","volume":"23","author":"Cheng","year":"2016","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.beem.2020.101434_bib78","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1210\/en.2015-2052","article-title":"ATR-101, a selective and potent inhibitor of acyl-CoA acyltransferase 1, induces apoptosis in H295R adrenocortical cells and in the adrenal cortex of dogs","volume":"157","author":"LaPensee","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2020.101434_bib79","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-020-00899-1","article-title":"A\u00a0phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma","author":"Smith","year":"2020","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.beem.2020.101434_bib80","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/annonc\/mdy335","article-title":"Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types","volume":"29","author":"Pare","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib81","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.beem.2020.101434_bib82","article-title":"The interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma","volume":"8","author":"Landwehr","year":"2020","journal-title":"J\u00a0Immunother Canc"},{"key":"10.1016\/j.beem.2020.101434_bib83","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib84","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-1321","article-title":"Dendritic cells, the T cell-inflamed tumor microenvironment and immunotherapy treatment response","author":"Garris","year":"2020","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-015-0047-3","article-title":"Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study","volume":"3","author":"Fay","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.beem.2020.101434_bib86","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib87","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib88","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013517","article-title":"Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: two case reports","volume":"97","author":"Mota","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.beem.2020.101434_bib89","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz014","article-title":"Development of an adrenocortical cancer humanized mouse model to characterize anti-PD1 effects on tumor microenvironment","volume":"105","author":"Lang","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2020.101434_bib90","article-title":"Disease progression after discontinuation of nivolumab for intolerable immunotherapy associated polymyalgia rheumatica in a patient with metastasized adrenocortical carcinoma: a case report and review of the literature","volume":"3","author":"Harrer","year":"2020","journal-title":"Clin Oncol Case Rep"},{"key":"10.1016\/j.beem.2020.101434_bib91","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1038\/s41467-018-06366-z","article-title":"Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors","volume":"9","author":"Gara","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.beem.2020.101434_bib92","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.beem.2020.101434_bib93","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib94","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.beem.2020.101434_bib95","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib96","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1210\/jc.2008-0050","article-title":"[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes","volume":"93","author":"Hahner","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib97","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1210\/jc.2012-3261","article-title":"[(1)(2)(3)I]Iodometomidate imaging in adrenocortical carcinoma","volume":"98","author":"Kreissl","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib98","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jc.2011-2765","article-title":"[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma","volume":"97","author":"Hahner","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib99","first-page":"105","article-title":"Treatment with 90Y\/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors","author":"Grisanti","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101434_bib100","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma - towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib101","doi-asserted-by":"crossref","first-page":"43016","DOI":"10.18632\/oncotarget.5513","article-title":"Inhibition of the Tcf\/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis","volume":"6","author":"Leal","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.beem.2020.101434_bib102","doi-asserted-by":"crossref","first-page":"22825","DOI":"10.18632\/oncotarget.15221","article-title":"Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.beem.2020.101434_bib103","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1158\/1078-0432.CCR-15-2256","article-title":"Identification of niclosamide as a novel anticancer agent for adrenocortical carcinoma","volume":"22","author":"Satoh","year":"2016","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib104","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","article-title":"Can we safely target the WNT pathway?","volume":"13","author":"Kahn","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beem.2020.101434_bib105","doi-asserted-by":"crossref","first-page":"12649","DOI":"10.1073\/pnas.1307218110","article-title":"Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2020.101434_bib106","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1073\/pnas.1508113112","article-title":"Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia","volume":"112","author":"Koo","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2020.101434_bib107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/JOE-18-0153","article-title":"Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice","volume":"238","author":"Funck-Brentano","year":"2018","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib108","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/jclinpath-2014-202514","article-title":"Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies","volume":"67","author":"Ross","year":"2014","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.beem.2020.101434_bib109","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fendo.2020.00219","article-title":"Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma","volume":"11","author":"Liang","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib110","first-page":"2695","article-title":"A\u00a0hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas","volume":"9","author":"Hadjadj","year":"2017","journal-title":"Aging (N Y)"},{"key":"10.1016\/j.beem.2020.101434_bib111","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12020-017-1270-0","article-title":"Palbociclib inhibits proliferation of human adrenocortical tumor cells","volume":"59","author":"Fiorentini","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2020.101434_bib112","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in combination with fulvestrant in women with hormone receptor-positive\/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib113","doi-asserted-by":"crossref","first-page":"33030","DOI":"10.18632\/oncotarget.26050","article-title":"Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response","volume":"9","author":"Nilubol","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.beem.2020.101434_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073959","article-title":"Single nucleotide polymorphism array profiling of adrenocortical tumors--evidence for an adenoma carcinoma sequence?","volume":"8","author":"Ronchi","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.beem.2020.101434_bib115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/ERC-15-0163","article-title":"Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome","volume":"22","author":"Ronchi","year":"2015","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.beem.2020.101434_bib116","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-11-2371","article-title":"Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma","volume":"18","author":"Simon","year":"2012","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beem.2020.101434_bib117","doi-asserted-by":"crossref","first-page":"950","DOI":"10.15252\/emmm.201607265","article-title":"gamma-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct","volume":"9","author":"Ran","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.beem.2020.101434_bib118","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2017.495","article-title":"A\u00a0phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma","volume":"118","author":"Cook","year":"2018","journal-title":"Br J Canc"},{"key":"10.1016\/j.beem.2020.101434_bib119","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jcb.27451","article-title":"MAPK\/ERK pathway inhibition is a promising treatment target for adrenocortical tumors","volume":"120","author":"Pereira","year":"2019","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.beem.2020.101434_bib120","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1677\/ERC-08-0101","article-title":"Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas","volume":"16","author":"Kotoula","year":"2009","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.beem.2020.101434_bib121","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/BF03346515","article-title":"Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors","volume":"32","author":"Masi","year":"2009","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2020.101434_bib122","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib123","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/cam4.1431","article-title":"Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation","volume":"7","author":"Hui","year":"2018","journal-title":"Canc Med"},{"key":"10.1016\/j.beem.2020.101434_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-015-0080-3","article-title":"Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma","volume":"5","author":"Bussey","year":"2016","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.beem.2020.101434_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128807","article-title":"Significant differences in the development of acquired resistance to the MDM2 inhibitor SAR405838 between in\u00a0vitro and in\u00a0vivo drug treatment","volume":"10","author":"Hoffman-Luca","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.beem.2020.101434_bib126","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2017.02.005","article-title":"A\u00a0phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours","volume":"76","author":"de Jonge","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.beem.2020.101434_bib127","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2020.101434_bib128","first-page":"2553","article-title":"The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials","volume":"10","author":"Guo","year":"2018","journal-title":"Canc Manag Res"},{"key":"10.1016\/j.beem.2020.101434_bib129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mce.2011.10.002","article-title":"Sonic hedgehog signaling during adrenal development","volume":"351","author":"Laufer","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2020.101434_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/cells7080107","article-title":"Targeting the multidrug transporter Ptch1 potentiates chemotherapy efficiency","volume":"7","author":"Hasanovic","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.beem.2020.101434_bib131","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ijc.31296","article-title":"Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in\u00a0vitro and in\u00a0vivo","volume":"143","author":"Hasanovic","year":"2018","journal-title":"Int J Canc"},{"key":"10.1016\/j.beem.2020.101434_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8020022","article-title":"Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors","volume":"8","author":"Rimkus","year":"2016","journal-title":"Cancers"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:44:36Z","timestamp":1778816676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X20300610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1521690X20300610"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2020.101434","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation therapies for adrenocortical carcinoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2020.101434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101434"}}